News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Napo Pharmaceuticals, Inc. Terminates Salix Pharmaceuticals, Ltd. (SLXP) for Breach of Agreement for Failure to Commercially Develop Crofelemer


11/10/2011 10:22:33 AM

SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. (“Napo”) announced today that, on November 4, 2011, it terminated its Collaboration Agreement with Salix Pharmaceuticals, Inc. (“Salix”) dated December 9, 2008 (the “Collaboration Agreement”) to commercially develop its first in class novel drug compound, crofelemer. The compound is a treatment for diarrhea, a life-threatening ailment that impacts millions of people across the world.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES